Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 8/20 | 0.67 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.61 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.59 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | HNF4A | P41235 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317521 | 0.91 | ACLY (0.68) | ACLYSERPINE1GRIK1KCNMA1SUCNR1 | |
| SCHEMBL1318525 | 0.91 | ACLY (0.67) | ACLYKCNMA1HDAC1DHFRHNF4A | |
| SCHEMBL13206537 | 0.87 | ACLY (0.59) | ACLYKCNMA1SUCNR1HDAC1DHFR | |
| SCHEMBL2270596 | 0.87 | ACLY (0.70) | ACLYSERPINE1GRIK1SUCNR1 | |
| SCHEMBL27696863 | 0.86 | ACLY (0.62) | ACLYSERPINE1GRIK1KCNMA1SUCNR1 | |
| SCHEMBL2272453 | 0.85 | ACLY (0.63) | ACLYKCNMA1SUCNR1HDAC1DHFR | |
| SCHEMBL1317243 | 0.85 | ACLY (0.56) | ACLYKCNMA1HDAC1DHFRHNF4A | |
| SCHEMBL13206145 | 0.85 | ACLY (0.56) | ACLYKCNMA1HDAC1DHFRHNF4A | |
| SCHEMBL1316555 | 0.85 | ACLY (0.56) | ACLYHDAC1DHFRHNF4AMCL1 | |
| SCHEMBL13206516 | 0.84 | ACLY (0.61) | ACLYSUCNR1HDAC1DHFRHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | ACLY 295/4885SERPINE1 470/4885TMPRSS4 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.